Search

Displaying results 7501 - 7510 of 8970 in total
  1. Drug

    Niperotidine

    go.drugbank.com/drugs/DB13760
    Investigational

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  2. Drug

    Alternaria alternata

    go.drugbank.com/drugs/DB10424
    Approved

    Alternaria alternata is a fungus which can provoke allergic reactions. Alternaria alternata extract is used in allergenic testing.

    Mixtures: Number Four Mold Mixture
  3. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  4. Drug

    Tandospirone

    go.drugbank.com/drugs/DB12833
    Investigational

    Tandospirone has been used in trials studying the treatment of Schizophrenia.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Tioxolone

    go.drugbank.com/drugs/DB13343
    Experimental

    Categories: Anti-Acne Preparations for Topical Use
  6. Drug

    Eprozinol

    go.drugbank.com/drugs/DB13395
    Experimental

    Categories: Drugs for Obstructive Airway Diseases
  7. Drug

    ABT-341

    go.drugbank.com/drugs/DB08044
    Experimental

    ABT-341 is a potent and selective DPP-4 inhibitor with a structure very similar to sitagliptin (in 2D; the 3D structure is significantly different). [A39406]

  8. Drug

    Iboctadekin

    go.drugbank.com/drugs/DB14920
    Investigational

    Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).

  9. Drug

    Girentuximab I-124

    go.drugbank.com/drugs/DB15025
    Investigational

    Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT).

  10. Drug

    Anti-GD2 monoclonal antibody 3F8

    go.drugbank.com/drugs/DB15388
    Investigational

    Anti-GD2 monoclonal antibody 3F8 is under investigation in clinical trial NCT00089258 (Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment).